Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 16/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537485 | 0.94 | PIK3CA (0.39) | PIK3CAPIK3CDPIK3CGPIK3R1MTOR | |
| SCHEMBL8254289 | 0.90 | IRAK4 (0.37) | HRH4HRH3PDE4APDE4BPDE4C | |
| SCHEMBL3922884 | 0.84 | HRH4 (0.48) | HRH4HRH3KCNH2HRH1 | |
| SCHEMBL4527848 | 0.82 | CYP1A2 (0.41) | PIK3CAPIK3CDPIK3CGPIK3R1MTOR | |
| SCHEMBL4525820 | 0.82 | PIK3CA (0.39) | HRH4PIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL4522361 | 0.81 | MAPT (0.43) | PDE4APDE4BPDE4CPDE4DPIK3CA | |
| SCHEMBL3931130 | 0.81 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CGPIK3R1MTOR | |
| SCHEMBL8146567 | 0.80 | HRH4 (0.51) | HRH4HRH3KCNH2HRH1 | |
| SCHEMBL3918629 | 0.77 | ABL1 (0.42) | PDE4APDE4BPDE4CPDE4DPIK3CA | |
| SCHEMBL4522932 | 0.77 | ADORA3 (0.47) | PIK3CAPIK3CDPIK3CGPIK3R1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | HRH4 1280/4885HRH3 1273/4885KCNH2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.